Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company AstraZeneca plc
DescriptionCombination of glycopyrrolate (PT001), a long-acting muscarinic antagonist (LAMA), and formoterol fumarate (PT005), a long-acting adrenergic receptor beta 2 agonist (LABA), delivered via a hydrofluoroalkane metered-dose inhaler
Molecular Target Adrenergic receptor beta 2 (ADRB2) ; Muscarinic receptor
Mechanism of ActionAdrenergic receptor beta 2 (ADRB2) agonist
Therapeutic ModalityMedical Devices: Drug/device combination
Latest Stage of DevelopmentPhase III
Standard IndicationChronic obstructive pulmonary disease (COPD)
Indication DetailsTreat chronic obstructive pulmonary disease (COPD); Treat moderate to very severe chronic obstructive pulmonary disease (COPD)
Regulatory Designation


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today